Please ensure Javascript is enabled for purposes of website accessibility

Why Intellia Therapeutics, Inc. Stock Lost 19.2% in March

By Keith Noonan - Apr 13, 2018 at 7:34AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The gene-editing company's stock hit a lifetime high last month but sold off on weaker-than-expected earnings results.

What happened

Intellia Therapeutics (NTLA 2.96%) stock lost 19.2% of its value in March, according to data provided by S&P Global Market Intelligence.

NTLA Chart

Data source: NTLA data by YCharts.

The bulk of the stock's movement last month occurred after the company posted fourth-quarter earnings results on March 14 and delivered results that fell short of the market's expectations.

A double helix on blue background.

Image source: Getty Images.

So what

Intellia shares rose early in the month, hitting a new lifetime high as the market reacted to favorable ratings coverage and bid the stock up in anticipation of its fourth-quarter earnings report. Barclays Capital raised its price target on the stock from $33 to $46 on March 7, and JMP Securities initiated coverage on the stock on March 9 and gave the company an "outperform" rating.

With the stock trading in the neighborhood of new lifetime highs, expectations were elevated in the leadup to the company's earnings release on March 14, and shares fell when top- and bottom-line performance came up short of the average analyst estimates. Sales for the quarter came in at $6.67 million and losses for the period came in at $0.61 per share, while the average analyst estimate had called for sales of $8.8 million and a loss of $0.44 per share. 

Now what

While the stock sold off after earnings, the company's earnings miss is probably of little significance to long-term shareholders. Intellia's CRISPR/Cas9 gene-editing-derived treatments are still in the pre-clinical phase, and most of the interest in the stock hinges on the revolutionary potential of these experimental therapies. As such, news on whether the company is progressing toward FDA approval for clinical trials will have much more significant implications for its valuation than earnings performance in the near term.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intellia Therapeutics Stock Quote
Intellia Therapeutics
$47.32 (2.96%) $1.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.